KLIFO, Europe’s largest independent provider of Clinical Trial Supply (CTS) packaging and distribution services, proudly announces that their new 6,500 sqm (65,000 sq ft) Abildager facility located in the Copenhagen area, has just received the official Manufacturing and Importation Authorisation by the Danish Medicines Agency.
This authorisation marks a significant milestone in KLIFO’s continued growth and commitment to delivering innovative, flexible, and sustainable CTS solutions for the pharmaceutical and biotech industries.
The purpose-built facility is designed to meet the increasing demand for advanced clinical trial supply services and includes:
- Significantly expanded capacity to support everything from small-scale studies to global Phase III and post-marketing trials
- Comprehensive temperature management from controlled room temperature to -80°C for storage, primary and secondary packaging and distribution
- Low-light capabilities for light-sensitive products
“The authorisation of our new facility represents a major step forward for KLIFO and the facility has already attracted significant interest from Nordic and international clients, reinforcing Copenhagen’s position as a leading life science hub in Europe,” said
René Pedersen, CEO. “We can now offer an even greater capacity to meet complex clinical trial supply chain needs globally while maintaining our focus on quality, compliance, and flexibility.”
The new facility combined with KLIFO’s experienced team and growing international reach, highly flexible solutions and compliance with global requirements means that KLIFO can accelerate project set-up, reduce turnaround times and minimise clinical supply chain issues.
